Myriad Genetic Mychoice News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Data from two Phase III studies showed at ESMO that patients with BRCA1/2 mutations and HRD are living longer with maintenance therapy with Lynparza alone and in combination with Avastin.

Rhode islandUnited statesIsabelle ray coquardMerck lynparzaPaul disilvestroGenentech avastinJonathan ledermannUniversity claude bernard lyonEuropean society for medical oncology congress onUniversity college london cancer instituteEuropean societyMedical oncology congressMyriad genetic mychoiceUniversity claude bernardInfants hospital